Anthony Klappa, MD
Interventional Cardiology · Springdale, ARNPI 1982998837
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (45.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 69.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2020 at $10,231 and has fallen 93.9% since, to $621 in 2025.
Across 115 payments — averaging $190.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$15K
- Inari Medical, Inc.$3K
- Abiomed$2K
- Medtronic$633
- BD$373
- Biotronik Inc.$207
- plus $802 from 16 others
What the payments were for
- Speaking & faculty fees$3732%
- Grants$10,00046%
- Travel & lodging$5,64526%
- Food & beverage$5,92227%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 36 | $15,198 |
| Inari Medical, Inc. | 20 | $2,946 |
| Abiomed | 5 | $1,792 |
| Medtronic(2 entities) | 10 | $633 |
| BD | 1 | $373 |
| Biotronik Inc. | 14 | $207 |
| Penumbra, Inc. | 2 | $159 |
| Pfizer | 7 | $107 |
| Edwards Lifesciences | 1 | $90 |
| Livanova USA, Inc. | 1 | $89 |
| Cardiovascular Systems Inc. | 2 | $62 |
| Stryker | 2 | $56 |
| Johnson & Johnson | 2 | $35 |
| Merck | 2 | $32 |
| Boston Scientific | 2 | $32 |
| Amgen | 2 | $30 |
| Philips North America LLC | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Bayer | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$2,693
- CT THROMBECTOMY SYSTEM KIT$2,693
- SUPERA$2,646
- Impella$1,650
- OPTIS$1,411
- COREVALVE EVOLUT R$521
- JETi Peripheral Catheter$132
- Optis Coronary Imaging System$129
- MitraClip$124
- PERCLOSE PROGLIDE$123
- Penumbra System$120
How this compares
$21,951 in reported general payments places this provider in the 85th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $128,316 |
| XareltoRivaroxaban | 51 | $56,122 |
| EntrestoSacubitril/Valsartan | 37 | $56,114 |
| JardianceEmpagliflozin | 14 | $16,872 |
| FarxigaDapagliflozin Propanediol | 12 | $15,407 |
| Repatha SureclickEvolocumab | 11 | $6,252 |
| Atorvastatin Calcium | 276 | $2,354 |
| Metoprolol Succinate | 115 | $1,365 |
| ClopidogrelClopidogrel Bisulfate | 145 | $1,342 |
| Losartan Potassium | 146 | $1,331 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 38 | $1,224 |
| Carvedilol | 116 | $859 |
| SotalolSotalol Hcl | 31 | $818 |
| Midodrine Hcl | 15 | $728 |
| Amlodipine Besylate | 134 | $653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $107 | $128,316132 claims |
| Johnson & JohnsonXarelto | $35 | $56,12251 claims |
| NovartisEntresto | $12 | $56,11437 claims |
| Boehringer IngelheimJardiance | $24 | $16,87214 claims |
| AstraZenecaFarxiga | $17 | $15,40712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Springdale
- Michael GreenSpringdale$10K
- Ahmad ElesberSpringdale$7K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Lena AwarJonesboro$43K
- Zubair AhmedFayetteville$36K
- Stephen BroughtonLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.